2019 New Drug Approvals: Hematology
Visit our New Drug Products page to stay up-to-date on the latest hematology drug approvals.
Anemias
New Drugs Approved in 2019
This slideshow gives you an at-glance view of all the new drug approvals in 2019. For the latest drug approvals visit our New Drug Products page.
Pegcetacoplan Superior to Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Trial
Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol (PEG) polymer that inhibits the complement cascade centrally at C3.
MPR Weekly Dose Podcast: Episode 13
This week on the Weekly Dose we talk about the first lung transplant due to vaping-related illness; A new approval for patients with beta thalassemia; Opioids in osteoarthritis; A new, free test to help diagnose COPD; and news of a potential new therapy for hypercholesterolemia.
Roxadustat Superior to Epoetin Alfa in New Dialysis Patients
Newly released safety data also show that roxadustat is associated with reduced cardiovascular risks compared with epoetin alfa.
Reblozyl Approved for Anemia in Beta Thalassemia
The FDA has approved Reblozyl (luspatercept–aamt; Celgene and Acceleron) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.
Ultomiris Receives Approval for Atypical Hemolytic Uremic Syndrome
The FDA has approved Ultomiris (ravulizumab-cwvz; Alexion) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adult and pediatric patients aged 1 month and older.
Danicopan Gets Breakthrough Therapy Status for Paroxysmal Nocturnal Hemoglobinuria
Results of a trial showed a mean increase in hemoglobin of 2.6g/dL in patients who completed 24 weeks of treatment.
Iron Deficiency Anemia Treatments
Recommendations for the management of iron deficiency anemia including oral and intravenous iron therapies.
Roxadustat Noninferior to Epoetin Alfa in Dialysis Patients
Patients undergoing dialysis were randomized to receive either roxadustat or epoetin alfa, 3 times per week for 26 weeks.
